Abeona Therapeutics Inc.

Abeona Therapeutics Inc.

ABEONYSE / NASDAQHealthcareSmall cap

$2.42-$0.03 (-1.2%)

Last close · Data as of Nov 20, 2026

Market cap
$331.7M
P/E
4.7x
EV / EBITDA
3.5x
Revenue
$5.8M
Net margin
1223.1%
ROCE
-47.1%

-42.7% over the last year

Abeona Therapeutics Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-47.4%
3M
-59.4%
6M
-54.5%
1Y
-42.7%
5Y
Hidden
  • This period includes a one-day price step on 23 Apr 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.03 (-1.2%) from $2.45 to $2.42 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ABEO, bought on each weekday since 2021.

News & filings

What Abeona Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was -76.3 million US dollars in fiscal 2025, a year of net profit.

Strengths (1)

  • Return on equity of 44.7%.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.

Read moreShow less

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Sector
Healthcare
Shares outstanding
53.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$331.7M
P/E
4.7x
P/B
2.1x
EV / EBITDA
3.5x
EV / Sales
47.8x
P/S
57.0x
52-week high
$7.46
52-week low
$2.29

Profitability

Operating margin
-1536.9%
Net margin
1223.1%
EBITDA margin
1350.3%
ROE
44.7%
ROCE
-47.1%
ROIC
70.8%
ROA
32.4%
Asset turnover
0.03

Growth

Revenue
$5.8M
Revenue CAGR, 3Y
60.3%
Net profit growth, 1Y
-211.7%
Free cash flow
-$84.3M

Solvency

Current ratio
6.93
Debt / Equity
0.16
Debt / Assets
0.11
CFO / Net profit
-1.07
Cash / Market cap
23.6%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$5.8M
Cost of revenue$3.4M
Gross profit$2.4M
Operating expenses$91.9M
Research and development$26.8M
Selling, general and administrative$65.0M
Operating income-$89.5M
Interest and other$160.7M
Pretax income$71.3M
Tax and other$100.0k
Net income$71.2M

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Abeona Therapeutics Inc. revenue and net profit by fiscal year
Abeona Therapeutics Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.4M-$39.7M
FY2023$3.5M-$54.2M
FY2024$0.00-$63.7M
FY2025$5.8M$71.2M

Cash flows

FY2025: -$76.3M from operations, -$84.3M free after investment (dashed).

Abeona Therapeutics Inc. operating and free cash flow by fiscal year
Abeona Therapeutics Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$43.5M-$43.6M
FY2023-$37.0M-$37.3M
FY2024-$56.0M-$58.5M
FY2025-$76.3M-$84.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$5.8M
EBITDA
$78.6M
Net profit
$71.2M
Cash from operations
-$76.3M
Free cash flow
-$84.3M
Revenue CAGR, 3Y
60.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$5.8M$78.6M$71.2M-$84.3M44.7%—-211.7%

Monthly returns

Month-by-month returns of ABEO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$219.6M
Liabilities$60.4M
Equity$159.2M
Paid-in capital$900.6M
Retained earnings-$742.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ABEO highlighted.

P/E against peers

ABEO trades at 4.7x earnings against a peer median of -1.6x.

  1. Abeona Therapeutics Inc. (this company)4.7x

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Larimar Therapeutics, Inc., Rocket Pharmaceuticals, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Abeona Therapeutics Inc.ABEOthis company$331.7M4.7x2.1x44.7%3.5x
Larimar Therapeutics, Inc.LRMR$341.8M—4.4x-212.2%—
Enanta Pharmaceuticals, Inc.ENTA$341.1M-4.2x5.3x-126.5%-5.1x
Verastem, Inc.VSTM$339.2M-1.6x5.9x-366.2%-1.1x
Simulations Plus, Inc.SLP$336.4M-5.2x2.7x-51.9%20.8x
908 Devices Inc.MASS$333.5M17.1x2.3x13.6%-12.6x
Humacyte, Inc.HUMA$330.8M-8.1x106.4x-1313.4%-15.5x
Organogenesis Holdings Inc.ORGO$319.1M8.6x1.1x12.3%3.7x
Rocket Pharmaceuticals, Inc.RCKT$318.8M-1.4x1.2x-80.5%-1.3x
Peer median—-1.6x3.5x-103.5%-1.3x

Year-to-date ROI

ABEO since 1 January, against earlier years.

Historical volatility

ABEO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Abeona Therapeutics Inc. operating margin by fiscal year
Abeona Therapeutics Inc. operating margin by fiscal year
DateOperating margin
FY2022-3209.9%
FY2023-1377.1%
FY2024—
FY2025-1536.9%
LineFY2025
Cost of revenueCost Of Revenue$3.4M
Gross profitGross Profit$2.4M
Operating expensesOperating Expense$91.8M
Research and developmentResearch And Development$26.8M
Depreciation and amortisationDepreciation And Amortization In Income Statement—
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement—
Total expensesTotal Expenses$95.3M
Pretax incomePretax Income$71.3M

Learn while you research

Academy chapters picked for Abeona Therapeutics Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 4.7 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →